Literature DB >> 1519852

Amelioration of sleep apnea by salicylate-induced hyperventilation.

G Pillar1, R Schnall, M Odeh, A Oliven.   

Abstract

It is well documented that upper airway (UAW) muscle activity is augmented in response to increased respiratory drive, the overall effect being an improvement in UAW patency. We have recently shown that salicylate-induced ventilatory stimulation increased UAW muscle electrical activity and decreased UAW resistance and collapsibility in anesthetized dogs. In the present study, we evaluated the effect of respiratory stimulation produced by high therapeutic doses of aspirin on sleep in nine patients with previously diagnosed sleep apnea. A control, all-night, polysomnographic sleep study, including oximetry and ventilatory monitoring by inductive plethysmography, was compared with a second study undertaken after patients ingested 8 to 10 g of aspirin over a period of 4 to 5 h. Aspirin ingestion resulted in high therapeutic salicylate serum levels (33 +/- 2.5 mg/dl, mean +/- SE) the following morning and was associated with marked ventilatory stimulation. Mean sleep duration and the relative partitioning of sleep stages were not affected by aspirin. However, aspirin-induced hyperventilation was associated with a significant non-rapid decrease in periodic breathing and the frequency of both obstructive and mixed apneas in all non-rapid eye movement (REM) sleep stages. The total number of apneas over the whole night was reduced in all subjects and on average fell from a control rate of 42 +/- 7 to 28 +/- 7 apneas/h (p less than 0.01). Similarly, the mean duration of apneas fell from 23 +/- 2 to 20 +/- 1 s (p less than 0.05), and the overall time spent in apneas decreased from 17 +/- 3 to 10 +/- 3 min/h (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519852     DOI: 10.1164/ajrccm/146.3.711

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  1 in total

1.  Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting beta2-Agonist.

Authors:  Kurt Rasche; Hans-Werner Duchna; Julia Lauer; Maritta Orth; Sylvia Kotterba; Torsten Thomas Bauer; Adrian Gillissen; Gerhard Schultze-Werninghaus
Journal:  Sleep Breath       Date:  1999       Impact factor: 2.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.